Research Grants

	Children's Cancer Research FUND Families and Friends Who care Click Here to Download Children's Cancer Research Fund's 2011 Grant Application In the twenty years of funding, CCRF has just awarded its 72nd research grant! Since Children's Cancer Research Fund is not the arm of any one hospital, it is able to fund research on a national level. 2011 REDELL, MICHELE, M.D., Ph.D. Texas Children's Cancer and Hematology Centers Houston, Texas Identifying Chemotherapy Resistance Mechanisms in Relapsed Acute Myeloid Leukemia SEPE, DANA, M.D. Center for Childhood Cancer Research & Division of Oncology, The Children's Hospital of Philadelphia Philadelphia, Pennsylvania* Pharmacokinetics in Pediatric Cancer Patients DRISSI, RACHID, Ph.D. Cincinnati Childrens Hospital Medical Center Cincinnati, Ohio* Biology Studies in the First Phase I Trial of a Telomerase Inhibitor in Children with Refractory of Recurrent Solid Tumors and Lyphomas 2010* BARBIERI, EVELINE, M.D., Ph.D. Baylor College of Medicine Houston, Texas Sestrins Modulate p53-Dependent Responses to Chemotherapy in Neuroblastoma. KRIVTSOV, ANDREI, Ph.D. Childrens Hospital Boston Boston, Massachusetts* Preclinical Assessment of Ctnnb1 Suppression for Treatment of MLL-AF9 AML/LSC. ROY, UPAL BASU, Ph.D., M.P.H. New York University Medical Center New York, New York* Targeting Sox2-positive Stem Cells in Osteosarcoma. STAKE, NORIKO, M.D. University of California, Davis Sacramento, California* Leukemia-Specific Ligands Against Childhood Acute Lymphoblastic Leukemia. 2009* ARA, TASNIM, M.D., Ph.D. Childrens Hospital Los Angeles Los Angeles, California Role of IL-6/STAT-3 and AKT signaling in Neuroblastoma Chemoresistance and Tumor progression in Bone Marrow Microenvironment. RAINUSSO, NINO, M.D. Baylor College of Medicine Houston, Texas* Immunotherapy to Target Cancer Stem Cells in Pediatric Osteosarcoma. SATWANI, PRAKASH, M.D. Columbia University New York, New York* A Novel Chemotherapy (Romidepsin) and Immunotherapy (Natural Killer Cell) Based Approach in Pediatric Leukemia and Lymphomas: Potential for Targeted Adoptive Cellular Immunotherapy (ACI). VROOMAN, LYNDA, M.D. Dana-Farber Cancer Institute Boston, Massachusetts* Volumetric Bone Mineral Density Changes During and After Childhood Acute Lymphoblastic Leukemia Therapy. 2008* KESHELAVA, NINO, M.D. Childrens Hospital Los Angeles Los Angeles, California Overcoming Neuroblastoma Drug Resistance with Histone Deacetylase Inhibitors and Flavopiridol. MITTLEMAN, STEPHEN D., M.D., Ph.D. Childrens Hospital Los Angeles Los Angeles, California* Exploring How Obesity and Adipocytes Affect Childhood Cancer. OKCU, MEHMET F., M.D., Ph.D. Baylor College of Medicine, Texas Childrens Hospital Houston, Texas* Glutathione S-Transferase P1 Variation and Survival in Children with High Risk Neuroblastoma. SONG, HAE-RI, M.D. Childrens Hospital Los Angeles Los Angeles, California* Nuclear Factor I A gene, and Astrocytic Lineage Gene, in Glioma Formation. 2007 ASGHARZADEH, SHAHAB, M.D. Childrens Hospital Los Angeles Los Angeles, California* Genomics of Metastatic Neuroblastomas Lacking MYCN* Amplification. GREGORY, MARK A., Ph.D. University of Colorado Health Sciences Center Aurora, Colorado Identifying Candidates for Targeted Therapy in Combination with FLT3 Inhibition for the Treatment of Acute Myeloid Leukemia. WELLS, JAMES, M.D. Bringham and Women's Hospital, Inc. Boston, Massachusetts* EWS-Flil as an Immuno-Therapeutic Target for Ewing's Sarcoma. 2006* ARMSTRONG, MICHAEL B., M.D., PH.D. University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Impact of N-myc on Chemoresistance in Neuroblastoma. HELLER, KEVIN N., M.D. The Rockefeller University New York, New York* Epstein-Barr Virus Immunity and Lymphoma. KEATING, AMY K., M.D. UCHSC at Fitzsimmons, Pediatrics Aurora, Colorado* Mer Receptor Tyrosine Kinase as a Biological Marker and Therapeutic Target for Pediatric Leukemia. RABIN, KAREN, M.D. Texas Children’s Cancer Center Houston, Texas* Acute Lymphoblastic Leukemia in Down Syndrome: An Investigation of Molecular Genetics and Host Toxicity. 2005* BARRY, ELLY FALZARANO, M.D. Dana Farber Cancer Institute Boston, Massachusetts Pharmacogenomics of Doxorubicin-induced Cardiotoxicity. KEATES-BALEEIRO, JENNIFER, M.D. Vanderbilt Children's Hospital Nashville, Tennessee* Testing Novel Therapeutics in a Mouse Model if Inv (16). ZACHAROULIS, STERGIOS, M.D. Childrens Hospital Los Angeles Los Angeles, California* Preclinical Evaluation of VEGFR2/EGFR Inhibition in Combination with MetronomicTemozolomide in a Mouse Model of High Grade Gliomas. 2004* HAINING, W. NICHOLAS, B.M., B.CH. Dana-Farber Cancer Institute Boston, Massachusetts Targeting telomerase as a cancer antigen: a phase 1 pediatric tumor vaccine trial. KARAJANNIS, MATTHIAS, A., M.D. Memorial Sloan-Kettering Cancer Center New York, New York* Role of pro-angiogenic factors in leukemia-stroma interactions. ONEL, KENAN, M.D., PH.D. The University of Chicago Chicago, Illinois* The Identification of Novel Biomarkers and Therapeutic Targets in Pediatric ALL by Correlative Analysis of Genome Copy Number Alterations, mRNA Expression, and Clinical Characteristics. 2003* ASGHARZADEH, SHAHAB, M.D. Childrens Hospital Los Angeles Los Angeles, California Gene Expression Profiles of Metastic Neuroblastomas without MYCN Amplification Predict Outcome. ERDREICH-EPSTEIN, ANAT, M.D., PH.D. Childrens Hospital Los Angeles Los Angeles, California* The antiangiogenic effect of alphav-integrin inhibition combined with fenretinide in mouse models of human brain tumors. REID, GREGOR, M.D., PH.D. BC Research Institute for Child and Family Health Vancouver, British Columbia* *Development of immune therapy for ETV6-AML1 positive leukemia using a novel mouse model.
	*as of 2000
	2002 APLENE, RICHARD, M.D. Children's Hospital of Philadelphia Philadelphia, Pennsylvania * Genetic Polymnorphisms and Anthracycline Associated Cardiac Toxicity. BROWN, VALERIE I., M.D., PH.D. Children's Hospital of Philadelphia Philadelphia, Pennsylvania * Evaluation of mTOR Inhibitors and the Role of IL-7 Signaling in Lymphoid Malignancies. GRAHAM, DOUGLAS K., M.D., PH.D. University of Colorado Cancer Center Denver, Colorado * Evaluation of role of proto-oncogene c-mer in acute lymphocytic leukemia. PUNAM, MALIK, M.D. Childrens Hospital Los Angeles Los Angeles, California * In Vivo Effects of Erythropoietin Receptor Signaling in Pediatric Tumors. 2001 BATRA, SANDEEP, M.D. Childrens Hospital Los Angeles Los Angeles, California * Activity of fenretinide (4-HPR) and 4-HPR plus safingol in preventing disease progression against pediatric Ewing's Sarcoma (ES) and Primitive neuroectodermal Tumors (PNET) cell lines In Vitro and In Vivo. MALIK, PUNAM, M.D. Childrens Hospital Los Angeles Los Angeles, California * Role of Erythropoietin and Erythropoietin Receptor in Pediatric Tumors. ROOD, BRIAN, M.D. Children's National Medical Center Washington, D.C. * Methylation of the O⁶-methylguanine methyltransferase (MGMT) gene promoter as a prognostic factor in pediatric high grade glioma and medulloblastoma. WEIGEL, BRENDA, M.D. University of Minnesota Medical School Minneapolis, Minnesota * Combination Immunotherapy and Chemotherapy for Rhabdomyosarcoma. 2000 MAURER, BARRY J., M.D., PH.D. Childrens Hospital Los Angeles Los Angeles, California * Novel Retinoid Combinations with Selective Cytotoxicity for Malignant Cells. WANG, LISA L., M.D. Baylor College of Medicine, Texas Children's Cancer Center Houston, Texas * Molecular Basis and Clinical Spectrum of Rothmund-Thomson Syndrome. 1999 SAVASAN, SUREYYA, M.D. Wayne State University Detroit, Michigan * In Vitro Drug-Induced Apoptosis as a Measure of Chemo- sensitivity in Childhood T-Cell Acute Lymphoblastic Leukemia. VAN TORNOUT, JAN M., M.D., M.S. Childrens Hospital Los Angeles Los Angeles, California * Evidence for Gene - Environmental Interaction(s) in the Etiology of Pediatric Brain Cancer. SWEETSER, DAVID A., M.D., PH.D. Fred Hutchinson Cancer Research Center Seattle, Washington * The Significance of Loss of Heterozygosity in the Patho- genesis and Prognosis of Pediatric de novo AML. 1998 Fu, Cecilia, M.D. USC School of Medicine/Childrens Hospital Los Angeles Los Angeles, California * Evaluation of Apoptotic Oncoproteins in Blast Cells from Pediatric Patients with Leukemia at Diagnosis and at Relapse. KESHELAVA, NINO, M.D. USC School of Medicine/Childrens Hospital Los Angeles, California * Resistance to Alkylating Agents in Neuroblastoma. 1997 MALONEY, KELLY, M.D. University of Colorado Health Sciences Center Denver, Colorado * Retrospective Analysis of Prognostic Import of TEL Rearrangements and Hyperdiploidy on Treatment Outcomes for Children with Standard Risks ALL treated with a Single Delayed Intensification. SHOHET, JASON, M.D. University of Texas Southwestern Medical Center Dallas, Texas * Analysis of Differentially Expressive Genes in Normal and Neoplastic B-Cells. 1996 ORCHARD, PAUL, M.D. University of Minnesota Minneapolis, Minnesota * Expression of anti-CD 19 scFv/zeta Chimeric Gene in Human NK Cells. ERDREICH-EPSTEIN, ANAT, M.D., PH.D. USC School of Medicine/Childrens Hospital Los Angeles Los Angeles, California * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric Neural Tumors. 1995 ERDREICH-EPSTEIN, ANAT, M.D., PH.D. USC School of Medicine/Childrens Hospital Los Angeles Los Angeles, California * Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric Neural Tumors. TAUB, JEFFREY, M.D. Children's Hospital of Michigan Detroit, Michigan * The Molecular Basis of Cytarabine Sensity of Down Syndrome Children. 1994 WEST, DANIEL C., M.D. Dana-Farber Cancer Institute/Harvard Medical School Boston, Massachusetts * Testing the feasibility of using the PCR Technique to measure the presence of Ewing's Sarcoma or Peripheral Neuraoecto- dermal Tumors. SCHMIDT, MARY LOU, M.D. Northwestern University Children's Memorial Hospital Chicago, Illinois * The Biologic Effects of Down-regulation of N-myc Oncogene Expression in Human Neuroblastoma. (continued study) 1993 HAMRE, MERLIN R., M.D., M.P.H. Children's Memorial Institute for Education and Research Chicago, Illinois * Mechanisms of Resistance to Nucleoside Analogue Inhibitors of S-Adenosyl-L-Homocysteine hydrolase in Murine and Human Neuroblastoma Tumor Cell Lines: Enzymatic and Genetic Determinants. WHITLOCK, JAMES, A., M.D. Vanderbilt University Medical Center Nashville, Tennessee * Acquired and Constitutional Alterations of p53 in the Devel- opment and Progression of Childhood Central Nervous System Tumors. 1992 EMANUEL, PETER D., M.D. University of Alabama at Birmingham Birmingham, Alabama * Mechanisms of Response and Effectiveness of 13-Cis Retinoic Acid in the Treatment of Juvenile Chronic Myelogenous Leukemia. TOMLINSON, GALE E., M.D., PH.D. University of Texas Southwestern Medical Center Dallas, Texas * A Search for predisposition factors in Breats/Sarcoma Cancer Families. SCHMIDT, MARY LOU, M.D. Northwestern University Children's Memorial Hospital Chicago, Illinois * The Biologic Effects of Down-regulation of N-myc Oncogene Expression in Human Neuroblastoma. SHANNON, KEVIN, M.D. University of California, San Francisco San Francisco, California * Mutations of the Neurofibromatosis and Ras Genes in Childhood Myeloproliferative Syndromes. 1991 MOULTON, THOMAS, M.D. Columbia University College of Physicians & Surgeons New York, New York * The Role of Classic Multidrug Resistance in Pediatric Solid Tumors. RAUCK, AMANDA M., M.D. Children's Hospital Columbus, Ohio * Urokinase and It's Receptor in Pediatric Cancers - the Tumor Biology of Wilms' Tumor and Neuroblastoma, Development and Metastasis. UMIEL, TEHILA, PH.D. Children's Hospital of Los Angeles Los Angeles, California * Isolation, Molecular Characterization and Induction of Differ- entiation of Mixed Lineage (Myeloid/Lymphoid) Precursors from Norman and Leukemic Human Bone Marrow. SCHMIDT, MARY LOU, M.D. Northwestern University Children's Memorial Hospital Chicago, Illinois * Inhibition of N-myc Gene Expression with Antisense N-myc RNA. HUANG, CHIEN-SHENG, M.D. University of California, San Diego La Jolla, California * Use of Ch14.18 and GM-CSF Neuroblastoma. VAN TORNOUT, JAN M.A., M.D. Children's Hospital of Los Angeles Los Angeles, California * The Use of Neural Networking in Pediatric Outcome of Childhood Cancer. TOMLINSON, GAIL E., M.D., PH.D. University of Texas Southwestern Medical Center Dallas, Texas * Constitutional p53 Mutations in Childhood Patients. 1990 SAYLORS, ROBERT L. III, M.D. Washington University School of Medicine St. Louis, Missouri * C-myc Activation in Medulloblastoma. SMITH, THOMAS J., M.D. National Jewish Center for Immunology and Respiratory Medicine Denver, Colorado * Vbeta Specificity of T-cell Leukemia and other T-cell Lymphoproliferative Disorders. VILLABLANCA, JUDITH, M.D. Children's Hospital of Los Angles Los Angeles, California * Significance of Cellular Proliferation in Neuroblastoma. 1989 WINICK, NAOMI J., M.D. University of Texas Southwestern Medical Center Dallas, Texas * 6-Mercaptopurine Metabolism in Children with Acute Lymphoblastic Leukemia. GREFFE, BRIAN, M.D. The Children's Hospital Denver, Colorado * Effect of L-Asparaginase on the regulatory coagulation proteins and vWF as a mechanism for thrombosis in children with leukemia and lymphoma.
	Children's Cancer Research Fund 1554 S. Sepulveda Boulevard, Suite 107 Los Angeles, California 90049 Phone: 310-444-0100 E-mail: ccrfkids@hotmail.com